Buspar Articles
Four Actavis generics gets US FDA approval
3 March 2008
Leading US pharmacy settles $50M Medicaid fraud case
20 November 2006
Bristol-Myers Squibb warned by FDA over Pravachol ads
18 August 2003
New generic moves from Michigan Blues
12 May 2003
B-MS settles US FTC/states
17 March 2003
B-MS settles US FTC/states
17 March 2003
Mylan reaches buspirone settlement with B-MS
3 March 2003
Mylan turnover up; guidance raised
10 February 2003
Update - B-MS ready to settle generics- blocking charges
13 January 2003
B-MS turnover down 14% in 2nd quarter
29 July 2002
AARP consumer hot-line for anti-generics suits
24 June 2002
B-MS sued over Taxol protection attempts
10 June 2002
US seniors group joins generics lawsuits
10 June 2002
Generic success sparks further competition
20 May 2002
Watson gets US OK on new use for Alora
15 April 2002
Bristol-Myers Squibb issues profit warning for 2002
15 April 2002
Bristol-Myers Squibb slumps as Vanlev data disappoints
25 March 2002
Watson sees 2001 revenues, income rise
25 February 2002
FTC OKs US patent suits against B-MS.
21 January 2002
US FTC probes Orange Book patent listings
14 January 2002
US states file BuSpar lawsuit against B-MS
13 December 2001
Stock Commentary - New York
22 November 2001
B-MS earnings driven by Glucophage
24 October 2001
House panel OKs US pediatric test bill
15 October 2001
Consumer groups sue S-P over Claritin claims
15 August 2001
Teva gets tentative FDA appro for generic Buspar
9 August 2001
Stock Commentary - New York
14 June 2001
Schering-Plough, etc sued over K-Dur20
11 June 2001
US consumer groups pledge more lawsuits
15 May 2001
US consumer groups in court over generics
11 May 2001
US seniors sue B-MS over generic BuSpar
27 April 2001
B-MS 1st-qtr pharma sales up 8% at $3.7B
26 April 2001
Stock Commentary - New York
11 April 2001
Stock Commentary - New York
5 April 2001
Stock Commentary - New York
22 March 2001
Bristol-Myers Squibb's "solid year" sees net earnings rise 13%
25 January 2001
FDA wins lawsuit over BuSpar listing
23 January 2001
Stock Commentary - New York
30 November 2000
US consumerists' anger at B-MS' patent move
29 November 2000
Watson sees revenue loss on B-MS action
23 November 2000
B-MS net earnings increase 13%
23 October 2000
B-MS up on strong sales of Glucophage
24 July 2000
Generic approvals for Norton in UK
1 July 1999
Elan Completes Ziconotide Phase III In Neuropathic Pain
15 December 1998
Elan's Combi Nicotine Patch A Partial Success
24 November 1998
US Quarterly Financial Results Round-Up
23 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Elan Acquires Sano In Deal Valued At $375 Million
17 December 1997
Transdermal ADHD Patch Looks Promising
12 June 1997
"Solid Growth" At Bristol-Myers Squibb
5 May 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Sano's Buspirone Patch For Depression/Anxiety
3 February 1997
B-MS and Sano Corp Form Alliance
2 September 1996
Volume Growth Boosts B-MS' First Quarter
6 May 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
New Production For Alkaloida
29 January 1996
Disease ManagementThe Way Forward
15 May 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
Arcturus Begins Phase II Trials
5 December 1994
PROZAC APPROVED FOR OCD IN USA
14 March 1994
BOOTS IN NEW PRODUCT DEAL WITH ESTEVE
1 November 1993
BRISTOL-MYERS LOSES BUSPAR PATENT DECISION
12 July 1993
SPANISH FIRM ESTEVE INTERNATIONALIZES
10 May 1993
COCENSYS TARGETING NEUROACTIVE STEROIDS
19 April 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
WORLD CNS MARKET IS LARGE AND FRAGMENTED
22 February 1993
MEIJI SEIKA R&D UPDATE
9 November 1992
ALZHEIMER'S DISEASE: US CONCERN
27 January 1992
Showing 1-86 of 86 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
